Insight Molecular Diagnostics Other Non-Current Liabilities 2014-2025 | IMDX

Insight Molecular Diagnostics other non-current liabilities from 2014 to 2025. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Insight Molecular Diagnostics Annual Other Non-Current Liabilities
(Millions of US $)
2024 $38
2023 $40
2022 $46
2021 $77
2020 $7
2019 $0
2018 $0
2017 $0
2016 $0
2015 $0
2014 $0
2013 $0
Insight Molecular Diagnostics Quarterly Other Non-Current Liabilities
(Millions of US $)
2025-06-30 $41
2025-03-31 $38
2024-12-31 $38
2024-09-30 $49
2024-06-30 $42
2024-03-31 $43
2023-12-31 $40
2023-09-30 $29
2023-06-30 $29
2023-03-31 $27
2022-12-31 $46
2022-09-30 $60
2022-06-30 $66
2022-03-31 $72
2021-12-31 $77
2021-09-30 $52
2021-06-30 $51
2021-03-31 $8
2020-12-31 $7
2020-09-30 $8
2020-06-30 $11
2020-03-31 $11
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical Information Systems $0.072B $0.002B
Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn.
Stock Name Country Market Cap PE Ratio
Veeva Systems (VEEV) United States $44.502B 54.47
Doximity (DOCS) United States $12.809B 56.99
Tempus AI (TEM) United States $12.797B 0.00
Hims & Hers Health (HIMS) United States $9.972B 81.70
IRhythm Technologies (IRTC) United States $5.509B 0.00
Hinge Health (HNGE) United States $4.528B 0.00
Inspire Medical Systems (INSP) United States $2.705B 39.76
Privia Health (PRVA) United States $2.677B 198.27
Heartflow (HTFL) $2.609B 0.00
Phreesia (PHR) United States $1.937B 0.00
10x Genomics (TXG) United States $1.778B 0.00
Enovis (ENOV) United States $1.749B 9.24
Omnicell (OMCL) United States $1.529B 29.45
Schrodinger (SDGR) United States $1.454B 0.00
Azenta (AZTA) United States $1.372B 59.84
Clover Health Investments (CLOV) United States $1.348B 0.00
Claritev (CTEV) United States $1.174B 0.00
Evolent Health (EVH) United States $1.133B 0.00
Fulgent Genetics (FLGT) United States $0.674B 0.00
Zepp Health (ZEPP) Netherlands $0.550B 0.00
Veradigm (MDRX) United States $0.534B 0.00
Standard BioTools (LAB) United States $0.493B 0.00
Talkspace (TALK) United States $0.445B 133.00
Butterfly Network (BFLY) United States $0.410B 0.00
Carlsmed (CARL) United States $0.363B 0.00
TruBridge (TBRG) United States $0.300B 52.60
Health Catalyst (HCAT) United States $0.257B 0.00
Outset Medical (OM) United States $0.247B 0.00
SOPHiA GENETICS SA (SOPH) Switzerland $0.224B 0.00
Nyxoah SA (NYXH) Belgium $0.214B 0.00
KORU Medical Systems (KRMD) United States $0.196B 0.00
CapsoVision (CV) United States $0.184B 0.00
MDxHealth SA (MDXH) Belgium $0.164B 0.00
CareCloud (CCLD) United States $0.160B 7.27
ImmunoPrecise Antibodies (IPA) Canada $0.115B 0.00
American Well (AMWL) United States $0.113B 0.00
EUDA Health Holdings (EUDA) Singapore $0.082B 0.00
Pulmonx (LUNG) United States $0.072B 0.00
111 (YI) China $0.061B 0.00
P3 Health Partners (PIII) United States $0.060B 0.00
HeartBeam (BEAT) United States $0.044B 0.00
Zhongchao (ZCMD) China $0.026B 0.00
Precipio (PRPO) United States $0.025B 0.00
PROFUSA (PFSA) United States $0.017B 0.00
Healthcare Triangle (HCTI) United States $0.014B 0.00
Bullfrog AI Holdings (BFRG) United States $0.012B 0.00
Predictive Oncology (POAI) United States $0.010B 0.00
Strata Skin Sciences (SSKN) United States $0.008B 0.00
HeartSciences (HSCS) United States $0.008B 0.00
MSP Recovery (MSPR) United States $0.005B 0.00
Movano (MOVE) United States $0.004B 0.00
Evaxion - (EVAX) Denmark $0.004B 0.00
Mobile-health Network Solutions (MNDR) Singapore $0.004B 0.00
Tivic Health Systems (TIVC) United States $0.003B 0.00